Affärsvärlden assigns a speculative Buy rating to the medtech company Raysearch in a comment on Tuesday.
The stock is falling sharply on the exchange today following the third-quarter report. Order intake and revenue growth were good. Gross margin was weak, however, and the operating margin was clearly worse than expected. The company is nevertheless retaining its full-year margin target. The newspaper assesses that reaching it will be challenging.
“Investors who like medtech companies and are not deterred by the risk level and large quarterly fluctuations can consider taking a position. We assign a speculative Buy rating,” Affärsvärlden writes in its conclusion.
